Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts.

Archives: Reports

MARA Rating Company
September 7, 2026

Revtorpyk / gedatolisib for HR-Positive/HER2-Negative Advanced Breast Cancer as of August 2026

MARA Rating Company September 7, 2026

Xocova / Ensitrelvir for Post-Exposure Prophylaxis of COVID-19 as of August 2026

MARA Rating Company September 7, 2026

ENSACOVE / Ensartinib for ALK-Positive Advanced NSCLC as of August 2026

MARA Rating Company September 7, 2026

LIPFENDRA / Enlicitide for treating primary hypercholesterolemia or mixed dyslipidemia as of August 2026

MARA Rating Company September 7, 2026

Centanafadine for Adult ADHD as of August 2026

MARA Rating Company September 7, 2026

Capivasertib for PTEN-deficient metastatic androgen pathway modulation-naive or -sensitive prostate cancer as of August 2026

MARA Rating Company September 7, 2026

Etcamah / Camizestrant for Locally Advanced or Metastatic ER-Positive/HER2-Negative Breast Cancer as of August 2026

MARA Rating Company September 7, 2026

Cosibelimab / UNLOXYT for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma as of August 2026

MARA Rating Company September 7, 2026

Sonrotoclax for treating relapsed or refractory mantle cell lymphoma after prior BTK inhibitor exposure as of June 2026

MARA Rating Company June 16, 2026

Tarlatamab for relapsed Extensive-Stage Small Cell Lung Cancer After Two or More Prior Lines of Therapy as of June 2026

MARA Rating Company June 16, 2026